SeekingAlpha · Oct 27, 2026
TN
NASDAQ · TNGX
Tango Therapeutics, Inc.
Healthcare · Biotechnology
$22.72
Down-$0.96 (-4.23%)
Updated Nov 3, 2026, 12:56 AM
SID Score
5.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.01B
- P/E ratio
- -6.93
- Dividend yield
- 0.00%
- 52-week range
- $7.37 – $34.39
- Volume
- 5.28M
- Avg. volume
- 3.27M
Price performance · TNGX
TNGX price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
TNGX closed at $22.72 after 20 trading sessions, down 1.56% for the selected period.
- Last close
- $22.72
- Period change
- -1.56%
- Period low
- $21.83
- Period high
- $27.93
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $22.11 | $22.75 | $21.71 | $22.72 | 5.28M |
| Oct 29, 2026 | $22.38 | $23.59 | $22.36 | $22.53 | 3.37M |
| Oct 28, 2026 | $22.855 | $23.71 | $22.14 | $22.23 | 3.31M |
| Oct 27, 2026 | $22.02 | $23.51 | $21.81 | $22.89 | 3.32M |
| Oct 26, 2026 | $23.41 | $23.9533 | $21.995 | $22.195 | 5.37M |
| Oct 23, 2026 | $25.54 | $25.94 | $22.6801 | $23.34 | 15.85M |
| Oct 22, 2026 | $26.67 | $27.98 | $25.94 | $27.93 | 5.96M |
| Oct 21, 2026 | $25.55 | $27.60 | $25.35 | $26.98 | 5.56M |
| Oct 20, 2026 | $23.95 | $25.35 | $23.20 | $25.25 | 2.67M |
| Oct 19, 2026 | $22.49 | $23.86 | $22.36 | $23.53 | 1.87M |
| Oct 16, 2026 | $23.12 | $23.17 | $21.82 | $22.04 | 3.69M |
| Oct 15, 2026 | $22.265 | $22.96 | $21.785 | $22.70 | 2.9M |
| Oct 14, 2026 | $21.98 | $23.02 | $21.52 | $22.19 | 3.44M |
| Oct 13, 2026 | $23.85 | $24.11 | $21.85 | $22.22 | 9.62M |
| Oct 12, 2026 | $23.57 | $24.47 | $23.344 | $24.17 | 2.87M |
| Oct 9, 2026 | $22.60 | $24.12 | $22.44 | $23.81 | 3.1M |
| Oct 8, 2026 | $21.57 | $22.68 | $20.98 | $22.57 | 5.07M |
| Oct 7, 2026 | $21.64 | $22.46 | $21.38 | $21.83 | 3.39M |
| Oct 6, 2026 | $23.16 | $23.16 | $21.36 | $21.90 | 4.35M |
| Oct 5, 2026 | $23.29 | $23.56 | $22.25 | $23.08 | 1.94M |
Latest TNGX news
The latest Smart Investors Daily articles mentioning TNGX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
TNGX research
Overview
Company profile and research snapshot.
Company profile
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $13.50
- Implied upside
- —
- Analysts
- 15
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 29, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 16, 2026 | William Blair | Outperform | — |
| Aug 18, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 12, 2026 | Guggenheim | Buy | — |
| Jul 17, 2026 | Mizuho | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 23, 2026
Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response Rate
Tango Therapeutics (NASDAQ:TNGX) said it plans to begin a global Phase III trial in the first half of 2027 evaluating vopimetostat in combination with daraxonrasib as a first-line treatment for patients with MTAP-deleted metastatic pancreatic ductal adenocarcinoma, or PDAC. The company outlined the
Benzinga · Oct 23, 2026
Crude Oil Surges 4%; SLB Shares Jump Following Upbeat Q3 Earnings
U.S. stocks fell Friday: Dow -1.12%, S&P 500 -0.43%, Nasdaq -0.13%. Energy and oil rose; SLB gained 7% on strong results.
Benzinga · Oct 23, 2026
Tango Therapeutics Announces Results From Ongoing Phase 1/2 Study Of Vopimetostat In Combination With Daraxonrasib In Patients With Metastatic Pancreatic Ductal Adenocarcinoma And Non-Small Cell Lung Cancer; Study Demonstrated 82% Objective Response Rate, Median PFS Not Yet Reached, And 9M PFS Rate Of 88%, In 22 Patients
Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to delivering breakthrough targeted therapies that extend and improve the lives of patients with cancer, today announced
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
